Rebyota market forecast points to growth through 2026
The Business Research Company says the Rebyota market is expected to expand as recurrent C. difficile infections, antibiotic use and microbiome research drive demand for microbiota-based therapies. North America held the largest share in 2025, while the report points to broader regulatory support and wider clinical adoption ahead.
Why it matters: - Rebyota sits in a growing market tied to recurrent Clostridioides difficile infection, a condition that is difficult to manage when antibiotics keep disrupting gut microbiota. - The report frames Rebyota as part of a broader shift toward microbiome-based therapies and live biotherapeutic products. - The market’s growth could matter for gastroenterology practices, microbiome drug developers and patients seeking options that reduce recurrence.
What happened: - The Business Research Company published its Rebyota Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Rebyota market is gaining attention as microbiome therapies reshape treatment approaches for recurrent infections. - The report forecasts market expansion through 2026. - North America held the largest share of the Rebyota market in 2025.
The details: - Rebyota is a microbiota-based therapeutic option for preventing or treating recurring Clostridioides difficile infections. - The therapy works by restoring disrupted gut microbiota after infection or antibiotic use. - Historical growth in the market has been driven by high recurrence rates in CDI, limits of antibiotic-only treatment, rising awareness of gut microbiome health, hospital-acquired infections and early success in microbiota-based therapies. - Future growth is expected to come from rising recurrent CDI incidence, broader regulatory support for microbiome drugs, wider adoption in gastroenterology, more investment in microbiome research and better patient outcomes. - The report highlights increased use of microbiota-based treatments, stronger focus on preventing recurrent CDI, broader acceptance of live biotherapeutic products, more therapies aimed at restoring gut microbiota balance and improved clinical results against antibiotic-resistant infections. - Antibiotic use is a key market driver because antibiotics can disrupt gut microbiota and contribute to recurrent CDI. - In April 2023, the Centers for Disease Control and Prevention reported that U.S. community pharmacies dispensed about 251 million oral antibiotic prescriptions in outpatient settings, equal to 752 prescriptions per 1,000 people. - Rising clinical trials also support the market, with the report pointing to demand for innovative treatments, medical research progress and personalized medicine. - In May 2023, clinicalTrials.gov listed 452,604 clinical studies worldwide, including 64,838 actively recruiting participants. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample is available here. - The full report is available here.
Between the lines: - The report’s emphasis on antibiotic resistance and recurrent infection suggests Rebyota is being positioned as a complement to, not a replacement for, antibiotic care. - The regional note on North America points to a mature early market, while the broader region list signals that future growth may depend on how quickly other markets adopt microbiome therapies. - The inclusion of forecasting dashboards and strategic scoring tools suggests the report is aimed at investors, manufacturers and commercial planners as much as clinicians.
What's next: - The report expects broader clinical adoption, more regulatory support and continued investment in microbiome research to shape the market through 2026. - Ongoing clinical trial activity and rising recurrent CDI cases are likely to remain central to demand. - The market will also be watched for further uptake of live biotherapeutic products and therapies focused on restoring gut microbiota balance.
The bottom line: - Rebyota’s market story is being driven by a strong clinical need: recurrent CDI remains hard to solve with antibiotics alone, and microbiota-based therapies are gaining traction as an alternative approach.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Analysis
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.